Results 211 to 220 of about 17,033 (261)

Antiviral resistance and direct-acting antiviral agents for HCV

Antiviral Therapy, 2012
Direct-acting antiviral (DAA) agents specifically target viral proteins. Two DAAs have been already been approved for the treatment of HCV infection and many more are in development. DAA treatment of HCV infection, however, leads to the selection of viral variants (produced by the error-prone HCV polymerase) that are resistant to the DAA agent in use ...
Aloia, A., Locarnini, S., Beard, M.
openaire   +3 more sources

Management of direct-acting antiviral agent failures

Journal of Hepatology, 2015
Failure to respond to the approved combinations of multiple direct-acting antiviral agents is relatively low in hepatitis C virus treatment registration studies, with rates of 1% to 7%, depending on the patients' baseline characteristics. In real life, failure is slightly higher, likely because of lower compliance.
Maria, Buti, Mar, Riveiro-Barciela, Rafael, Esteban   +2 more
openaire   +2 more sources

Benefits of Direct-Acting Antivirals for Hepatitis C

Annals of Internal Medicine, 2017
Emerging data show that direct-acting antivirals (DAAs) improve clinical outcomes in hepatitis C virus (HCV).
Anna S, Lok, Raymond T, Chung, Hugo E, Vargas, Arthur Y, Kim, Susanna, Naggie, William G, Powderly   +5 more
openaire   +2 more sources

Direct-acting antiviral retreatment patterns for hepatitis C

Journal of Managed Care & Specialty Pharmacy, 2022
BACKGROUND: Despite the strong efficacy of direct-acting antivirals (DAAs) against the hepatitis C virus, many patients require a second regimen of DAA treatment. However, limited research exists to characterize rates of retreatment across different DAA agents or potential factors that may increase retreatment risk.
Shaquib Al, Hasan, Daniel G, Dauner, Abhijeet, Rajpurohit, Joel F, Farley   +3 more
openaire   +2 more sources

Chronic Hepatitis C and Direct Acting Antivirals

Surgical Pathology Clinics, 2018
The hepatitis C virus (HCV) is the most common blood-borne infection in the United States and is the most common cause of end-stage liver disease requiring liver transplant. Over the last 10 years, direct acting antiviral therapies have revolutionized HCV treatment, increasing the cure rates from less than 50% to more than 90% in those who reach access
Maria, Westerhoff, Joseph, Ahn
openaire   +2 more sources

Resistance to Direct-Acting Antivirals

Current Hepatitis Reports, 2012
Viral resistance corresponds to the selection, during treatment, of pre-existing viral variants less susceptible to the drug’s inhibitory activity because they bear amino acid substitutions altering the drug target. Hepatitis C virus (HCV) drugs in development can be split into two groups according to their barrier to resistance.
openaire   +1 more source

Resistance to direct-acting antiviral agents

Current Opinion in HIV and AIDS, 2015
This article examines the dynamics and factors underlying hepatitis C virus (HCV) resistance, along with their impact on daily clinical management of HCV-infected patients.Across available treatment-regimens, GT-3 is the most difficult-to-cure genotype, but also genotype-1a may show lower success-rates compared with genotype-1b.
Valeria, Cento, Stephane, Chevaliez, Carlo Federico, Perno   +2 more
openaire   +2 more sources

Interferon free therapy with direct acting antivirals for HCV

Liver International, 2013
AbstractThe current treatment for hepatitis C virus (HCV) genotype 1 chronic infection is the addition of direct‐acting antivirals (DAA) with a protease inhibitor (telaprevir or boceprevir) to the pegylated interferon (PEG‐IFN) plus ribavirin (RBV) regimen.
Tarik, Asselah, Patrick, Marcellin
openaire   +2 more sources

Extrahepatic manifestations of HCV: the role of direct acting antivirals

Expert Review of Anti-infective Therapy, 2017
Hepatitis C virus (HCV) represents a major health concern, as nearly 3 million people become newly infected by this pathogen annually. The majority of infected individuals fail to clear the virus, and chronicity is established. Chronic HCV patients are at high risk for liver disease, ranging from mild fibrosis to cirrhosis and severe hepatocellular ...
María Laura, Polo, Natalia, Laufer
openaire   +2 more sources

Controversies of Direct-Acting Antivirals in Hepatocellular Carcinoma

Surgical Oncology Clinics of North America
Therapy for chronic hepatitis C virus infection with direct-acting antiviral agents (DAAs) has been highly successful in achieving sustained virological response (SVR) with associated improvements in liver dysfunction, liver-related mortality, and transplant-free survival.
Ifrah, Fatima, Neehar D, Parikh, Alisa, Likhitsup   +2 more
openaire   +2 more sources